Scientists reported a mechanistic link between dysfunctional mitochondria and chronic inflammation in aging that centers on epigenetic activation of inflammatory genes. In a Nature paper titled “Mitochondrial metabolism and epigenetic crosstalk drive SASP,” teams from Mayo Clinic and Sanford Burnham Prebys Medical Discovery Institute described how senescent cells leverage mitochondria-derived acetyl-CoA to enable chromatin modifications that open inflammatory loci. The study builds on the senescence-associated secretory phenotype (SASP) concept by showing that inflammatory signaling alone is insufficient—cells also require metabolic input from mitochondria to switch inflammatory genes on. The researchers identified acetyl-CoA production as a key mediator, tied to histone and chromatin accessibility changes. They also highlighted a promising therapeutic target arising from the pathway. For drug developers targeting aging-associated inflammation, the work points to an intervention opportunity that connects cellular energy metabolism to epigenetic regulation. That linkage may broaden the palette beyond senolytics toward metabolic-epigenetic modulators designed to suppress SASP output.